These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31879844)

  • 1. Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study.
    Cadenas-Menéndez S; Álvarez Vega P; Oterino Manzanas A; Alonso Lecue P; Roig Figueroa V; Bedate Díaz P; Ortiz de Saracho J; Cifrián Martínez JM
    Am J Cardiovasc Drugs; 2020 Oct; 20(5):481-487. PubMed ID: 31879844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kondo T; Matsushita M; Minamino T; Nakanishi N; Okano Y; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Hatta M; Sasayama S
    Curr Med Res Opin; 2020 Jun; 36(6):921-928. PubMed ID: 32298185
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
    Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
    Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China.
    Chen YC; Dai HL; Liu CL; Li J; Ji QS; Cao YS; Xiao J; Jian R; Zhuo JM; Luo XC; Gu H
    Curr Med Res Opin; 2024 Sep; 40(9):1455-1464. PubMed ID: 39044676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
    J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.
    Safdar Z; Thakur A; Frost A
    South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
    Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies.
    Chin KM; Channick R; Kim NH; MacDonald G; Ong R; Martin N; Senatore A; McLaughlin VV
    Adv Ther; 2024 Nov; 41(11):4205-4227. PubMed ID: 39316293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
    van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
    Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of macitentan for the treatment of pulmonary arterial hypertension.
    Selej M; Romero AJ; Channick RN; Clozel M
    Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan.
    Tynan T; Hird K; Hannon T; Gabbay E
    J Int Med Res; 2019 May; 47(5):2177-2186. PubMed ID: 30975046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
    Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.